Vivus, Why the Slide? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vivus, Why the Slide?

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mkilloran who wrote (3988)	1/20/2000 7:29:00 AM
From: Frostman	Read Replies (1) of 3991

Thursday January 20, 4:03 am Eastern Time Company Press Release VIVUS Announces Higher Than Expected Fourth Quarter Earnings Per Share Company Expects To Report Between $0.40 and $0.42 EPS MOUNTAIN VIEW, Calif.--(BW HealthWire)--Jan. 20, 2000--VIVUS, Inc. (Nasdaq:VVUS - news) today announced that the Company expects to report earnings per share (''EPS'') between $0.40 and $0.42 for its fourth quarter of 1999. The increase in EPS is primarily due to additional revenues recorded as part of the resolution of financial obligations related to the return to VIVUS of marketing and distribution rights for MUSE® (alprostadil) from AstraZeneca. Complete details of the Company's quarterly and year end financial results will be available in a press release to be issued on January 26, 2000 at the close of market. VIVUS invites shareholders and the financial community to participate in its conference call which will be held at 4:30 p.m. Eastern Time on January 26, 2000. The call can be accessed via a live webcast on the Internet at www.vcall.com or www.streetfusion.com. VIVUS, Inc. is the developer and manufacturer of MUSE and ACTIS®, two innovations in the treatment of men with erectile dysfunction (''ED''), also known as impotence. The Company's objective is to become a global leader in the development and commercialization of innovative therapies for the treatment of sexual dysfunction and urologic disorders in men and women. VIVUS has ongoing research and development programs in female sexual dysfunction and male premature ejaculation. The company recently filed a New Drug Application with the FDA for ALIBRA®, its second-generation male ED treatment.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next